The fertility company Spermosens reports, as planned, no revenue during the fourth quarter. The operating loss decreased.The operating result was -2.1 million SEK (-2.4). Cash flow amounted to -2.2 million SEK (0.5). Cash and cash equivalents amounted to 6.8 million SEK (0.7)."We are making significant progress in introducing Juno-Checked in the major markets. Our goal is to reach clinics, laboratories and patients through innovative companies that combine strong commercial networks with a focus on male infertility and patient-centered care. We are in contact with several companies in the US, Europe and Asia. Our memoranda of understanding with Sapyen and RSI Technology Group are important steps forward," comments CEO Tore Duvold.He further highlights the importance of being able to integrate the company's technology into modern laboratories and clinics. Here, Spermosen is working to develop a system, Generation 3, which, according to Duvold, is progressing according to plan and is expected to be ready during the first half of 2026.Spermosens, SEK mQ4-2025Q4-2024ChangeNet sales00Operating result-2.1-2.4Cash flow-2.20.5Cash and cash equivalents6.80.7871.4%